Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.80 and traded as low as $1.02. Akari Therapeutics shares last traded at $1.10, with a volume of 57,287 shares changing hands.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on Akari Therapeutics in a report on Tuesday. They issued a “sell” rating on the stock.
Read Our Latest Report on AKTX
Akari Therapeutics Stock Up 1.9 %
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Read More
- Five stocks we like better than Akari Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- Can TikTok Stock Picks Really Make You Rich?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- The “Quality” Rotation: Back to Basics Investing
- What Investors Need to Know to Beat the Market
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.